Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636577 | 0.93 | CXCR4 (0.46) | CXCR4DRD2DRD3 | |
| SCHEMBL1794475 | 0.84 | CXCR4 (0.42) | CXCR4DRD2DRD3MOGAT2ABCB1 | |
| SCHEMBL1204854 | 0.81 | CXCR4 (0.42) | CXCR4DRD2DRD3MOGAT2ABCB1 | |
| SCHEMBL14619669 | 0.81 | CXCR4 (0.47) | CXCR4DRD2DRD3MOGAT2ABCB1 | |
| SCHEMBL1204852 | 0.81 | CXCR4 (0.67) | CXCR4DRD2DRD3MOGAT2ABCB1 | |
| SCHEMBL1636324 | 0.80 | CXCR4 (0.46) | CXCR4DRD2DRD3 | |
| SCHEMBL12552340 | 0.80 | CXCR4 (0.51) | CXCR4DRD2DRD3MOGAT2PRMT5 | |
| SCHEMBL1638572 | 0.79 | CXCR4 (0.45) | CXCR4DRD2DRD3 | |
| SCHEMBL1794340 | 0.78 | CXCR4 (0.54) | CXCR4DRD2DRD3PRMT5WDR77 | |
| SCHEMBL1798336 | 0.77 | DRD2 (0.50) | DRD2DRD3MOGAT2ABCB1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | CXCR4 86/4885DRD2 175/4885DRD3 283/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | CXCR4 100/4885DRD2 257/4885DRD3 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.